PT-141 (Research Grade)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
PT-141 (Research Grade) is listed as sexual health / melanocortin.
- •Sexual dysfunction (men & women)
- •Libido enhancement
Regulatory status: Research-grade not FDA-approved; FDA-approved analog = Vyleesi (bremelanotide).
Structure & Properties
Compound: PT-141 (Research Grade); also known as Palatin precursor.
Pharmacologic class: Sexual Health / Melanocortin.
Known delivery routes: Subcutaneous, Intranasal.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
MC3R/MC4R agonist — centrally activates hypothalamic melanocortin pathways; enhances sexual arousal independent of hormonal levels.
- •On-demand libido enhancement in both sexes
- •Centrally mediated, hormone-independent
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Phase II/III data led to Vyleesi approval
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
SubQ or intranasal 45–60 min before anticipated activity. Max ~1 dose per 24 hrs.
Potential interactions and combinations to avoid
- •Uncontrolled hypertension
- •Melanotan II — same class
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Nausea
- •Flushing
- •Transient BP elevation
- •Compounded purity concerns
Contraindications
- •Uncontrolled hypertension
- •Cardiovascular disease
- •History of melanoma, dysplastic nevi, or numerous/atypical moles
- •Uncontrolled hypertension or significant cardiovascular disease
- •Fitzpatrick type I skin with extensive sun exposure and no dermatologic surveillance
- •Concurrent PDE-5 inhibitors or antihypertensives without medical oversight (blood-pressure swings)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.5–2 mg PRN
Frequency: As needed (max 1×/24h)
Cycling: PRN only.
Subcutaneous
45–60 min before activity.
Insulin syringe. Abdomen or thigh. Rotate sites.
Intranasal
Research alternative — faster onset (~30 min).
Nasal spray. 1 spray per nostril.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Kisspeptin-10 for research stacks
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is PT-141 (Research Grade)?
In plain words
PT-141 is a lab-made chain of seven amino acids, the building blocks of proteins. It activates signals in the brain involved in sexual desire and arousal rather than raising hormone levels. Researchers study it for low sexual desire and other sexual difficulties in women and men. Research-grade products are not FDA-approved and may have purity problems; known effects of bremelanotide include nausea, flushing, and a temporary rise in blood pressure.
Technical definition
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from melanotan II, an analog of α-melanocyte-stimulating hormone. It acts as a melanocortin receptor agonist, including at MC3R and MC4R, influencing central pathways involved in sexual desire and arousal rather than replacing sex hormones. Research-grade PT-141 is not FDA-approved; Vyleesi contains the same active compound, bremelanotide, and is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Function
Dosing
Recommended Time of Day
45–60 minutes before sexual activity; not more than once in 24 hrs.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
PRN only.
Timing & Interactions
- ·Uncontrolled hypertension
- ·Melanotan II — same class
- ·Kisspeptin-10 for research stacks
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on PT-141 (Research Grade) and sync them to Vial Lab.
Benefits
- ·On-demand libido enhancement in both sexes
- ·Centrally mediated, hormone-independent
Risks
- ·Nausea
- ·Flushing
- ·Transient BP elevation
- ·Compounded purity concerns
Contraindications
- ·Uncontrolled hypertension
- ·Cardiovascular disease
- ·History of melanoma, dysplastic nevi, or numerous/atypical moles
- ·Uncontrolled hypertension or significant cardiovascular disease
- ·Fitzpatrick type I skin with extensive sun exposure and no dermatologic surveillance
- ·Concurrent PDE-5 inhibitors or antihypertensives without medical oversight (blood-pressure swings)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research-grade not FDA-approved; FDA-approved analog = Vyleesi (bremelanotide)
Veterinary Use (Pets)
No established veterinary protocol for PT-141 (Research Grade). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.